Wilson Disease

• Impaired hepatic copper excretion into bile: ATP7B normally pumps approximately 40% of absorbed dietary copper into the biliary system for fecal excretion. Loss-of-function mutations prevent this critical excretory pathway, causing copper to accumulate progressively within hepatocytes. The remaining copper excretion pathways (through urine and intestinal secretion) are insufficient to maintain copper homeostasis, leading to toxic accumulation over years to decades. This mechanism explains why the disease manifests relatively late in life—only after sufficient copper burden develops.

• Reduced ceruloplasmin synthesis and copper transport: ATP7B dysfunction also impairs the incorporation of copper into ceruloplasmin, the major plasma copper carrier protein synthesized in the liver. Serum ceruloplasmin levels fall to <20 mg/dL (normal 20-40 mg/dL) due to both reduced synthesis and increased catabolism of apoceruloplasmins. This results in decreased plasma copper transport capacity and failure to deliver copper to peripheral tissues, while simultaneously allowing non-ceruloplasmin copper (free copper) to accumulate in serum and distribute to target organs. The pathological free copper is highly reactive and directly causes tissue damage through oxidative mechanisms.

• Free copper-mediated oxidative damage: Accumulated free copper catalyzes generation of reactive oxygen species (ROS) through Fenton chemistry (Cu²⁺ + e⁻ → Cu⁺; Cu⁺ + H₂O₂ → Cu²⁺ + OH• + OH⁻). These hydroxyl radicals cause lipid peroxidation of cellular membranes, damage to mitochondrial cristae, denaturation of proteins, and direct DNA damage. This oxidative injury particularly affects the brain (high oxidative metabolism), liver (primary copper accumulation site), and cornea (visible as Descenoscelis-type changes). The hepatocytes are especially vulnerable as they accumulate 5-10 times normal copper content, leading to chronic hepatocellular injury, inflammation, fibrosis progression, and eventual cirrhosis (often with micronodular features).

• Hepatocellular injury and cirrhosis progression: Copper deposition triggers hepatocyte apoptosis through multiple mechanisms including mitochondrial dysfunction, endoplasmic reticulum stress, and JNK pathway activation. Chronic hepatocyte death with replacement fibrosis leads to progressive cirrhosis, often with a distinctive micronodular pattern. Notably, some patients present with acute liver failure (fulminant hepatic failure) when copper burden suddenly exceeds the hepatocyte's tolerance threshold, possibly triggered by intercurrent illness or hemolysis. This acute presentation carries Coombs-negative hemolytic anemia (copper damages RBC membranes directly), extremely high transaminases (>2000 IU/L), and very low serum copper despite high free copper levels (due to massive hepatic release during necrosis).

• CNS copper accumulation and basal ganglia dysfunction: Copper deposits preferentially in the basal ganglia (particularly putamen and globus pallidus), substantia nigra, and midbrain structures, causing cell death and gliosis. The putaminal involvement explains the parkinsonian features (bradykinesia, rigidity, tremor), while damage to dopaminergic pathways contributes to progressive motor dysfunction. Brainstem involvement explains dysarthria, dysphagia, and ataxia. The copper-induced damage also impairs GABAergic and monoaminergic neurotransmission, contributing to behavioral changes and depression. Unlike Parkinson disease, Wilson disease neurological manifestations are often rapidly progressive and may include atypical features such as dystonia and spasticity due to the specific distribution of damage.

• Corneal and systemic manifestations from local copper deposition: Descemet membrane copper deposition forms the pathognomonic Kayser-Fleischer ring, which appears as a golden-brown discoloration at the Descemet membrane-corneal epithelial junction, typically first visible at the superior and inferior poles of the cornea (at 12 and 6 o'clock positions). These rings develop through progressive copper incorporation into the basement membrane and are present in virtually all patients with neurological Wilson disease but only 50% of those with purely hepatic presentation. Copper also deposits in bone (causing osteoarthritis-like changes), kidneys (causing proximal tubular dysfunction and aminoaciduria), and parathyroid glands (causing hypoparathyroidism and hypercalciuria).

• ATP7B gene mutations as the sole cause: Over 500 distinct mutations have been identified, including point mutations, deletions, insertions, and splice site variants. Certain mutations show ethnic clustering (e.g., the H1069Q mutation accounts for ~40% of European cases but is rare in Asian populations where other mutations predominate). The specific mutation may correlate with disease severity and phenotype—some mutations cause predominantly hepatic disease while others cause primarily neurological manifestations, though this correlation is imperfect. Patients must inherit two mutant alleles (either homozygous or compound heterozygous) for disease expression, as heterozygous carriers remain asymptomatic with normal or minimally elevated copper metabolism.

• Autosomal recessive inheritance pattern with variable expressivity: Parents of affected individuals are obligate carriers but remain asymptomatic. Siblings of an affected patient have a 25% risk of being affected (if both parents are heterozygous carriers), 50% risk of being carriers, and 25% risk of inheriting two normal alleles. The variable expressivity results from allelic heterogeneity, modifier genes, and unclear environmental factors. Genetic testing is available and should be offered to all siblings of diagnosed patients for early identification, though the absence of a known mutation does not exclude Wilson disease, and genetic results do not reliably predict phenotype or severity.

• Dietary copper intake as a triggering factor: While dietary copper intake is not the primary cause (normal copper absorption is intact), excessive copper ingestion may accelerate disease progression in genetically susceptible individuals. This is clinically relevant in advising patients about avoidance of high-copper foods (shellfish, nuts, chocolate, dried fruits) and copper-contaminated water (from copper pipes).

Hepatic Presentations

• Chronic hepatitis or cirrhosis: Patients with hepatic-predominant disease present with insidious onset of fatigue, abdominal distension (ascites), right upper quadrant discomfort, or jaundice. Hepatomegaly may be mild to moderate; splenomegaly indicates portal hypertension. Laboratory findings show mild-to-moderate transaminase elevation (usually <300 IU/L in chronic disease), hyperbilirubinemia, and hypoalbuminemia. Histology demonstrates mixed inflammatory infiltrate with Mallory-Denk bodies, portal fibrosis progressing to established cirrhosis (often with a distinctive micronodular pattern), and stainable hepatic copper at elevated levels (>250 μg/g dry weight, vs. normal <50 μg/g).

• Acute liver failure (fulminant hepatic failure): This dramatic presentation occurs in approximately 10-15% of Wilson disease patients and represents the most severe initial manifestation. Patients present with rapid onset (days to weeks) of jaundice, coagulopathy, hepatic encephalopathy (confusion, asterixis, personality changes), and hemolytic anemia. The hemolysis is Coombs-negative (direct antiglobulin test negative) because copper damages RBC membranes directly without antibody involvement—this is a critical diagnostic clue. Laboratory findings include extreme transaminase elevation (often >2000-3000 IU/L), profound hyperbilirubinemia (often >10 mg/dL), markedly elevated INR/PT (often >3 seconds), yet serum copper levels are paradoxically LOW despite high free copper (due to massive hepatic release of free copper into plasma; the copper exceeds binding capacity). This acute presentation carries high mortality (up to 50%) without urgent liver transplantation and represents a medical emergency.

Neurological Presentations

• Parkinsonian syndrome (most common neurological manifestation): Patients present with bradykinesia (slowed voluntary movements), rigidity (lead-pipe or cogwheel type), postural instability, and tremor—features suggesting Parkinson disease. However, Wilson disease typically presents before age 50 (much younger than idiopathic PD), with rapid progression over months to years (not the slow progression of PD), and with asymmetric onset. The tremor in Wilson disease is characteristically a wing-beating tremor (high-amplitude, low-frequency 4-6 Hz), most prominent with the limbs outstretched, unlike the resting tremor of Parkinson disease. Rigidity may be severe and disabling. Notably, dopaminergic medications (L-dopa, dopamine agonists) are INEFFECTIVE or may worsen symptoms in Wilson disease, which is a crucial diagnostic and clinical clue—if a young patient with apparent Parkinsonism worsens on levodopa, consider Wilson disease.

• Dystonic syndrome: Some patients present with prominent dystonia rather than parkinsonism, with sustained muscle contractions causing abnormal postures. Cervical dystonia (torticollis), orofacial dystonia, hand dystonia, or generalized dystonia may develop. This is often more disabling than parkinsonism and is less responsive to medical therapy.

• Ataxia and cerebellar signs: Intention tremor, dysmetria, dysdiadochokinesia, nystagmus, and gait ataxia reflect cerebellar involvement and brainstem pathology. Ataxia may present insidiously or acutely and can be profound and disabling.

• Dysarthria and dysphagia: Speech becomes progressively slurred, difficult to understand, with hypophonic, dysrhythmic features. Swallowing difficulty develops as bulbar muscles are affected, creating aspiration risk. These indicate brainstem copper deposition.

• Behavioral and psychiatric symptoms: Depression, anxiety, personality changes, impulsiveness, aggression, and psychosis may precede or accompany motor symptoms. These psychiatric manifestations are often overlooked as primary psychiatric disease, delaying correct diagnosis. Cognitive decline and dementia can occur with advanced disease.

• Seizures and myoclonus: Generalized tonic-clonic seizures or partial seizures may occur due to cortical copper deposition. Myoclonic jerks and tremor may be prominent. Seizures are not the primary feature but represent severe diffuse CNS involvement.

Physical Examination Findings

• Kayser-Fleischer rings: These golden-brown, greenish, or bronze-colored rings at the Descemet membrane-corneal epithelial junction are pathognomonic for Wilson disease and result from copper deposition in Descemet membrane. Rings typically appear first at the superior and inferior poles of the cornea (12 and 6 o'clock positions), progressing circumferentially with continued copper loading. Rings are present in >95% of patients with neurological symptoms but only 50% of those with purely hepatic disease (young children with early-stage disease may lack rings despite systemic copper accumulation). Examination requires slit-lamp ophthalmology for detection; they are not visible on routine eye examination. The presence of Kayser-Fleischer rings in a young patient with hepatic cirrhosis or movement disorder is virtually diagnostic.

• Sunflower cataracts: Anterior lens opacities with a characteristic sunflower pattern can develop from copper deposition in the lens epithelium. These are uncommon and usually develop in long-standing disease but when present are highly specific.

• Signs of hepatic decompensation: Spider angiomata, palmar erythema, jaundice, hepatomegaly, splenomegaly, ascites, and signs of hepatic encephalopathy (asterixis, altered mental status) reflect advanced cirrhosis and are more common in patients with acute presentations or delayed diagnosis.

• Hypoparathyroidism features: Hypocalcemia from parathyroid copper deposition may cause positive Chvostek or Trousseau signs, paresthesias, and tetany in severe cases.

Important Clinical Variants

• Presymptomatic patients identified through family screening: Asymptomatic siblings or relatives of affected patients may be detected through screening protocols (ceruloplasmin, 24-hour urinary copper, slit-lamp examination) before symptoms develop. Early diagnosis and treatment initiation in these patients results in excellent prognosis with prevention of disease manifestations.

• Pure hepatic phenotype: Some patients present with exclusively hepatic manifestations (cirrhosis, acute liver failure) without obvious neurological symptoms. However, subtle neurological findings may be present if sought carefully.

• Atypical presentations: Some patients present with osteoarthropathy (arthritis-like changes in large joints), hemolytic anemia as the prominent feature, hypoparathyroidism with hypocalcemia, or renal tubular dysfunction with aminoaciduria.

Clinical History and Suspicion

• Young age of presentation (typically 6-40 years old, peak 15-35 years)
• Family history of neurological disease, liver disease, or consanguinity
• Neurological symptoms: young-onset parkinsonism (unresponsive to dopaminergic therapy), dystonia, ataxia, behavioral changes, seizures
• Hepatological symptoms: jaundice, hepatomegaly, ascites, encephalopathy, or acute liver failure in a young person
• Presence of Coombs-negative hemolytic anemia
• Combination of hepatic and neurological symptoms in same patient

Key Laboratory Tests

• Serum ceruloplasmin level (<20 mg/dL is abnormal; normal 20-40 mg/dL): This is typically the first screening test and is reduced in >95% of symptomatic Wilson disease patients. Low serum ceruloplasmin is highly suggestive but NOT absolutely diagnostic, as it may be reduced in severe liver disease from other causes, malnutrition, and rare other conditions. However, ceruloplasmin >30 mg/dL makes Wilson disease very unlikely (though rare exceptions exist). Ceruloplasmin is a positive acute phase reactant that may normalize during inflammation, potentially missing early disease; serial measurements may be needed.

• 24-hour urinary copper excretion (>100 μg/24 hours is abnormal; normal <30-50 μg/24 hours): This test is highly specific for Wilson disease when elevated and represents excessive renal copper loss reflecting high free copper burden. A 24-hour urinary copper >100 μg/day combined with low ceruloplasmin is virtually diagnostic. Values of 50-100 μg/day are borderline. This test requires careful collection without copper contamination (use acid-washed containers or special collection kits).

• Serum free (non-ceruloplasmin-bound) copper (>25 μg/dL is abnormal; normal 10-15 μg/dL): Free copper is calculated as:

Immediate stabilisation (fulminant Wilsonian liver failure)

• Emergency transplant referral: AASLD practice guidance on Wilson disease directs that acute liver failure with hemolysis and coagulopathy be transferred immediately to a transplant center. Chelation alone does not reliably rescue these patients; liver transplantation is definitive because the graft supplies functional ATP7B, correcting the metabolic defect.
• Prognostic scoring: the revised (New) Wilson Index, based on bilirubin, INR, AST, white count and albumin, is used to identify patients who will die without a graft.
• Copper removal as a bridge: albumin dialysis/continuous renal replacement or therapeutic plasma exchange lowers circulating free copper and blunts hemolysis while awaiting an organ.

First-line therapy for symptomatic disease

• Chelators: D-penicillamine or trientine mobilise tissue copper and promote cupriuresis. AASLD accepts either; trientine is generally preferred when neurologic disease predominates or penicillamine is not tolerated, since penicillamine causes paradoxical early neurologic worsening in a subset of patients. Give supplemental pyridoxine with penicillamine (it is a B6 antagonist).
• Zinc salts: zinc acetate induces enterocyte metallothionein, which binds dietary copper and sheds it in stool — a negative copper balance without systemic chelation. Preferred for presymptomatic patients found on family screening, maintenance after de-coppering, and pregnancy.
• Diet: avoid shellfish, organ meats, nuts, chocolate, mushrooms, and copper-piped well water. Adjunctive only.

Escalation and long-term care

• Switch or combine chelator and zinc for inadequate cupriuresis or intolerance; monitor 24-hour urinary copper and non-ceruloplasmin copper for both under- and over-treatment.
• Therapy is lifelong; abrupt discontinuation can precipitate fulminant hepatic failure.

Contraindicated/ineffective

• Levodopa and dopamine agonists do not correct Wilsonian parkinsonism.
• Penicillamine in pregnancy should be avoided or dose-reduced (teratogenic, impairs wound healing); zinc is the safer option.
• Avoid hepatotoxins, particularly alcohol.

Disease-related

• Fulminant hepatic failure with Coombs-negative hemolysis (EMERGENCY): massive hepatocyte necrosis dumps free copper into plasma, lysing red cells. Signalled by jaundice with anemia, coagulopathy, and a disproportionately low alkaline phosphatase with very high bilirubin; requires transplant evaluation the same day.
• Cirrhosis and portal hypertension: chronic copper-driven oxidative injury and fibrosis; heralded by varices, ascites, thrombocytopenia, and hypoalbuminemia.
• Hepatocellular carcinoma: less frequent than in viral or alcohol cirrhosis but reported; AASLD surveillance imaging applies once cirrhosis exists.
• Fixed neurologic disability: untreated basal ganglia copper deposition causes irreversible dystonia, dysarthria, and dysphagia; aspiration pneumonia is the usual terminal event.
• Renal tubular dysfunction: copper injures the proximal tubule, producing Fanconi-type aminoaciduria, phosphaturia, renal tubular acidosis, and nephrolithiasis.
• Other organ deposition: hypoparathyroidism with tetany, arthropathy and osteopenia, cardiomyopathy with arrhythmia, pancreatitis, amenorrhea and recurrent miscarriage.

Treatment-related

• Early neurologic deterioration on penicillamine: abrupt mobilisation of hepatic copper raises circulating free copper and can worsen tremor, rigidity, and speech within weeks of starting therapy — sometimes irreversibly.
• Penicillamine autoimmune and marrow toxicity: hypersensitivity fever/rash, membranous nephropathy with proteinuria, lupus-like syndrome, drug-induced myasthenia gravis, Goodpasture-like pulmonary–renal disease, aplastic anemia, and elastosis perforans serpiginosa. Check urinalysis and CBC serially; cytopenias or new proteinuria mandate stopping the drug.
• Pyridoxine deficiency from penicillamine's antivitamin effect.
• Over-chelation copper deficiency: sideroblastic/refractory anemia, neutropenia, and a myelopathy resembling subacute combined degeneration; low urinary and non-ceruloplasmin copper confirms it.
• Zinc intolerance: gastritis and asymptomatic lipase/amylase elevation; poor adherence from nausea risks decompensation.

• The stem signature: a patient under 40 with liver disease plus a movement disorder or new psychiatric illness. Any young person with unexplained hepatitis, cirrhosis, or acute liver failure gets a ceruloplasmin.
• Best next step after low ceruloplasmin: **slit-lamp examination for Kayser-Fleischer rings and a 24-hour urinary copper. If results remain equivocal, liver biopsy with quantitative hepatic copper** is the confirmatory test; genetic testing of ATP7B is used mainly for family screening.
• Wing-beating tremor with the arms abducted and elbows flexed is the classic motor buzzword; face of the giant panda sign in the midbrain on T2 MRI is the imaging buzzword.
• Coombs-negative hemolytic anemia with acute liver failure is Wilson disease until proven otherwise — copper lyses red cells directly, with no antibody. In this setting look for a low alkaline phosphatase relative to a very high bilirubin and a high AST:ALT ratio.
• The association examiners test: young-onset parkinsonism that does not respond to levodopa. Wilson disease, not idiopathic Parkinson disease.
• Penicillamine pairs with pyridoxine, and penicillamine can transiently worsen neurologic symptoms — a reason trientine is often chosen for neurologic-predominant disease (AASLD).
• Zinc is the answer for asymptomatic siblings detected by screening, for maintenance, and in pregnancy; all first-degree relatives of an index case must be screened (autosomal recessive, 25% sibling risk).
• Distractors to avoid: a normal or high ceruloplasmin does not exclude Wilson disease — it is an acute-phase reactant and rises with inflammation, pregnancy, and estrogen use. Also, total serum copper is often low, not high, because most circulating copper normally rides on ceruloplasmin; the pathogenic pool is non-ceruloplasmin-bound copper. Finally, treatment is lifelong — stopping it can trigger fulminant failure.